Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 125, Issue 9, Pages 3338-3346Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI80004
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia (NHAMP
- MRC) CDF1 Fellowship [1025552]
- NHMRC [1021139, 1059862, 1013667, 1078671]
- Prostate Cancer Foundation of Australia [YI0510]
- Cancer Council of Queensland (CCQ) [1079876]
- Susan Komen for the Cure grant [IIR12221504]
- CCQ [1083776]
- National Health and Medical Research Council of Australia [1059862] Funding Source: NHMRC
Ask authors/readers for more resources
Cancer immunoediting explains the dual role by which the immune system can both suppress and/or promote tumor growth. Although cancer immunoediting was first demonstrated using mouse models of cancer, strong evidence that it occurs in human cancers is now accumulating. In particular, the importance of CD8(+) T cells in cancer immunoediting has been shown, and more broadly in those tumors with an adaptive immune resistance phenotype. This Review describes the characteristics of the adaptive immune resistance tumor microenvironment and discusses data obtained in mouse and human settings. The role of other immune cells and factors influencing the effector function of tumor-specific CD8(+) T cells is covered. We also discuss the temporal occurrence of cancer immunoediting in metastases and whether it differs from immunoediting in the primary tumor of origin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available